): Project 4, in its modified form, is a randomized, placebo-controlled, double-blind, three-armed lung cancer chemoprevention trial in former smokers.
Our specific aims are: (a) To determine the efficacy of 9-cis retinoic acid (9cRA) and 13- cis retinoic acid (13cRA) plus alpha-tocopherol in reversing biomarkers of lung carcinogenesis, such as genetic and histologic alterations of preneoplasia and in activating biomarkers of retinoid response in the bronchial epithelium of former smokers; (b) To correlate the reversal of histologic and genetic abnormalities with retinoid nuclear receptor activation in bronchial biopsies from patients enrolled on the chemoprevention trial; (c) To explore the retinoid signaling pathways that mediate retinoid actions, such as inhibition of growth and squamous differentiation in normal human bronchial epithelial (HBE) cells, and the role of specific nuclear receptors and target genes activated by the receptors. The accrual goal for the chemoprevention trial is 225 patients. Accrual has recently increased appreciably due to enhanced efforts in patient recruitment, and at the time of grant submission we expect to have reached 50 percent of the accrual goal. Changes in eligibility criteria and treatment schedule have been made in the clinical trial to enhance patient accrual and reduce treatment-associated toxicity, respectively. Progress has been made toward the completion of biomarker studies proposed in Aim 2 through close interactions between the two University of Texas Institutions participating in this SPORE. These investigations have revealed that genetic abnormalities such as loss of heterozygosity and genomic instability are prevalent on chromosomes 3p, 9p and 17p in the bronchial epithelium of former smokers. Other biomarkers studies investigating the expression of retinoic acid receptor (RAR)-beta and telomerase activity in bronchial biopsies are ongoing. Through an active, inter-institution collaboration between Drs. Jonathan Kurie and David Mangelsdorf, progress has been made in translational studies proposed in Aim 3, revealing the importance of c-Jun N-terminal kinase in retinoid signaling. Future directions of this collaboration will identify, through cDNA subtraction and gene array technologies, novel genes targeted by retinoid receptors that mediate growth inhibition of normal HBE cells and retinoid resistance in non-small cell lung cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-05S9
Application #
6662771
Study Section
Project Start
2000-09-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :

Showing the most recent 10 out of 1059 publications